MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Regeneron's Eylea HD Enough to Fend Off Biosimilars and Rivals

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Target's $2 Billion Bet Enough to Revitalize Growth

4 months ago

Is Q2 Holdings' Innovation Enough to Counter Market Skepticism

1 months ago

Is SmartRent's Sales Scaling Strategy Enough to Drive Growth

1 months ago

Is Zeta Global's AI Edge Enough to Drive Q4 Earnings Growth

4 months ago

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

GLP-1 drug adoption is accelerating as more patients use them for weight loss and an expanding list of diseases becomes treatable, intensifying competition among manufacturers.

GLP

Stock News•3 weeks ago

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Outlook Therapeutics' resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD was accepted by the FDA, advancing a potential new standard of care for retina diseases.

AMD

Stock News•1 months ago

EyePoint: DURAVYU's Durability Could Drive Significant Upside

EyePoint Pharmaceuticals' lead candidate, DURAVYU, is valued at ~$2.9B pre-dilution based on Phase 2 durability data for wet AMD and DME. Analysts project a potential $27/share valuation, representing...

AMD

Stock News•2 months ago

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?

Regeneron Pharmaceuticals enters Q1 earnings with expectations that robust Dupixent profits and Eylea HD uptake will offset declining legacy Eylea sales. Investors are monitoring whether these growth ...

REGN